JP2007525444A - 治療応答を誘導するための組成物 - Google Patents

治療応答を誘導するための組成物 Download PDF

Info

Publication number
JP2007525444A
JP2007525444A JP2006509414A JP2006509414A JP2007525444A JP 2007525444 A JP2007525444 A JP 2007525444A JP 2006509414 A JP2006509414 A JP 2006509414A JP 2006509414 A JP2006509414 A JP 2006509414A JP 2007525444 A JP2007525444 A JP 2007525444A
Authority
JP
Japan
Prior art keywords
cells
composition
tissue
drug
mcp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007525444A5 (https=
Inventor
マイケル フロイクス，
ウォルター ブルスゼウスキー，
Original Assignee
ヘリコニア コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘリコニア コーポレイション filed Critical ヘリコニア コーポレイション
Publication of JP2007525444A publication Critical patent/JP2007525444A/ja
Publication of JP2007525444A5 publication Critical patent/JP2007525444A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
JP2006509414A 2003-03-25 2004-03-25 治療応答を誘導するための組成物 Pending JP2007525444A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45770203P 2003-03-25 2003-03-25
US10/808,927 US20040191215A1 (en) 2003-03-25 2004-03-24 Compositions for induction of a therapeutic response
PCT/US2004/009526 WO2004087065A2 (en) 2003-03-25 2004-03-25 Compositions for induction of a therapeutic response

Publications (2)

Publication Number Publication Date
JP2007525444A true JP2007525444A (ja) 2007-09-06
JP2007525444A5 JP2007525444A5 (https=) 2009-04-02

Family

ID=32994882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509414A Pending JP2007525444A (ja) 2003-03-25 2004-03-25 治療応答を誘導するための組成物

Country Status (4)

Country Link
US (1) US20040191215A1 (https=)
EP (1) EP1605899A2 (https=)
JP (1) JP2007525444A (https=)
WO (1) WO2004087065A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010214019A (ja) * 2009-03-18 2010-09-30 Chiba Univ ノッチシグナルを利用した虚血組織再生方法
JP2023502785A (ja) * 2019-11-25 2023-01-25 ザ・ペン・ステイト・リサーチ・ファウンデイション ヒトグリア細胞をニューロンに変換するための組成物および方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20070111935A1 (en) * 2000-04-06 2007-05-17 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20050277576A1 (en) * 2000-04-06 2005-12-15 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US10281478B2 (en) 2000-04-06 2019-05-07 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
CN101001643A (zh) * 2004-06-21 2007-07-18 克里夫兰诊所基金会 用于干细胞归巢的ccr配体
US8048446B2 (en) * 2005-05-10 2011-11-01 Drexel University Electrospun blends of natural and synthetic polymer fibers as tissue engineering scaffolds
US20070004973A1 (en) * 2005-06-15 2007-01-04 Tan Sharon M L Tissue treatment methods
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
US8983570B2 (en) 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
US11224635B2 (en) 2007-03-27 2022-01-18 Venturis Thereuptics, Inc. Therapeutic angiogenesis for treatment of the spine and other tissues
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
CN101980714A (zh) * 2008-03-31 2011-02-23 奥古斯蒂努斯·巴德 借助干细胞或骨髓细胞进行组织再生的方法和组合物
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US8496911B2 (en) * 2009-07-29 2013-07-30 Vatrix CHF, Inc. Tissue stabilization for heart failure
WO2011044443A2 (en) * 2009-10-09 2011-04-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Matricryptic ecm peptides for tissue reconstruction
WO2011119738A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Methods of treatment using stem cell mobilizers
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US20120093764A1 (en) * 2010-10-19 2012-04-19 Dipnarine Maharaj Treatment of diabetes using g-csf and hyperbaric oxygen
US9267934B2 (en) * 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
EP2846817B1 (en) * 2012-05-11 2018-10-17 Otto-von-Guericke-Universität Magdeburg Transplantation of modified monocytes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57118512A (en) * 1980-11-18 1982-07-23 Syntex Inc Microencapsulation of water-soluble polypeptide
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
JP2000501084A (ja) * 1995-11-24 2000-02-02 シェリング アクチェンゲゼルシャフト 均一な形態を有するマイクロカプセルの製造方法、並びにこの方法により製造されたマイクロカプセル
WO2000060054A1 (en) * 1999-04-06 2000-10-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
WO2002058723A2 (en) * 2001-01-24 2002-08-01 Schering Corporation Chemokines as adjuvants of immune response

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203290A (es) * 1983-09-19 1992-08-01 Liposome Co Inc Suministro localizado usando conjugados de fibronectina.
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
FI972433A0 (fi) * 1994-12-08 1997-06-06 Glaxo Group Ltd Rantes-peptidi ja fragmentteja sekä tätä sisältäviä tulehduksen hoitoon soveltuvia koostumuksia
JP2000502682A (ja) * 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
US6045565A (en) * 1997-11-04 2000-04-04 Scimed Life Systems, Inc. Percutaneous myocardial revascularization growth factor mediums and method
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US5980548A (en) * 1997-10-29 1999-11-09 Kensey Nash Corporation Transmyocardial revascularization system
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
US7067109B1 (en) * 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
IL125532A0 (en) * 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
US6363938B2 (en) * 1998-12-22 2002-04-02 Angiotrax, Inc. Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth
AU2457701A (en) * 1999-12-28 2001-07-09 Brown University Research Foundation Methods and products for tumor immunotherapy using cytokines
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US6660034B1 (en) * 2001-04-30 2003-12-09 Advanced Cardiovascular Systems, Inc. Stent for increasing blood flow to ischemic tissues and a method of using the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57118512A (en) * 1980-11-18 1982-07-23 Syntex Inc Microencapsulation of water-soluble polypeptide
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
JP2000501084A (ja) * 1995-11-24 2000-02-02 シェリング アクチェンゲゼルシャフト 均一な形態を有するマイクロカプセルの製造方法、並びにこの方法により製造されたマイクロカプセル
WO2000060054A1 (en) * 1999-04-06 2000-10-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
WO2002058723A2 (en) * 2001-01-24 2002-08-01 Schering Corporation Chemokines as adjuvants of immune response

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010214019A (ja) * 2009-03-18 2010-09-30 Chiba Univ ノッチシグナルを利用した虚血組織再生方法
JP2023502785A (ja) * 2019-11-25 2023-01-25 ザ・ペン・ステイト・リサーチ・ファウンデイション ヒトグリア細胞をニューロンに変換するための組成物および方法

Also Published As

Publication number Publication date
WO2004087065A2 (en) 2004-10-14
WO2004087065A8 (en) 2005-10-13
EP1605899A2 (en) 2005-12-21
WO2004087065A3 (en) 2007-11-15
US20040191215A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
JP2007525444A (ja) 治療応答を誘導するための組成物
JP2007525444A5 (https=)
KR101639827B1 (ko) 10 내지 20 미크론의 직경을 갖는 미세구를 포함하는 비경구형 조성물
JP5383757B2 (ja) 薬剤放出生分解性繊維インプラント
EP3691738B1 (en) Implantable bioreactor
US20130309304A1 (en) Compounds and methods
AU3368895A (en) Device for delivery of substances and methods of use thereof
JP2010517621A (ja) 治療用ハイブリッド移植型デバイス
CN101282652B (zh) 预血管化的装置及相关方法
CN105764538A (zh) 用于无免疫抑制剂的移植的装置、方法和使用
Choi et al. Lack of additional benefit of intracoronary transplantation of autologous peripheral blood stem cell in patients with acute myocardial infarction
KR102189850B1 (ko) 생리활성인자가 탑재된 고분자-세포 혼합 스페로이드 및 이의 제조방법
US20170095592A1 (en) Compositions For An Injectable, In Situ Forming Neuroscaffold And Methods Of Using The Same
CN110035742A (zh) 干细胞仿生微粒
WO2024233108A1 (en) Bone marrow microgels and uses thereof
CN101123977A (zh) 用于诱导治疗应答的组合物
CN112203667A (zh) 大包封的治疗性细胞、装置及其使用方法
KR102572188B1 (ko) 매크로-캡슐화 치료 세포 및 이의 사용 방법
CN121648162A (zh) 一种心功能制剂及其制备方法和应用
Zapata et al. Growth Factor Delivery Systems for the Treatment of Cardiovascular Diseases
HK1123161A (en) Prevascularized devices and related methods
CN106039288A (zh) 免疫耐受部位形成剂和免疫抑制性细胞的诱引剂

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100712